CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities.
Administration of in vitro expanded mesenchymal stromal cells (MSCs) represents a promising therapy for regenerative medicine and autoimmunity. Both mouse and human MSCs ameliorate autoimmune disease in syn-, allo- and xenogeneic settings. However, MSC preparations are heterogeneous which impairs th...
Main Authors: | Per Anderson, Ana Belén Carrillo-Gálvez, Angélica García-Pérez, Marién Cobo, Francisco Martín |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3790740?pdf=render |
Similar Items
-
Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
by: Virginia Di Paolo, et al.
Published: (2018-01-01) -
Endoglin Expression (CD105) in Ephithelial Ovarian Cancer
by: Rizkinov Jumsa, et al.
Published: (2018-04-01) -
CD105/ENDOGLIN EXPRESSION IN A MOUSE MODEL OF ACUTE MUSCLE CONTUSION
by: Antoanela Curici, et al.
Published: (2014-12-01) -
Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
by: Ana Nogués, et al.
Published: (2020-05-01) -
Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
by: Aldona Kasprzak, et al.
Published: (2018-12-01)